Research progress of primary pulmonary lymphoepithelioma-like carcinoma

doi:10.3760/cma.j.cn371439-20221121-00034

Abstract

Abstract:

Primary pulmonary lymphoepithelioma-like carcinoma （PPLELC） is a distinct type of lung cancer with histological profiles similar to nasopharyngeal carcinoma. The development is associated with EBV and plasma EBV DNA has predictive value in the progression and prognosis of PPLELC. PPLELC is different from some other types of lung cancer in that it has a low mutation rate of the classical lung cancer driver genes and targeted therapy is ineffective for it. Chemotherapy combined with immunotherapy may be the best first-line treatment option for patients with advanced PPLELC.

Key words: Herpesvirus 4, human, Immunotherapy, Pulmonary lymphoepithelioma-like carcinoma

Ma Pengcheng, Chen Yu. Research progress of primary pulmonary lymphoepithelioma-like carcinoma[J]. Journal of International Oncology, 2023, 50(3): 174-178.

References 43

[1]	Hu Y, Ren S, Liu Y, et al. Pulmonary lymphoepithelioma-like carcinoma: a mini-review[J]. Onco Targets Ther, 2020, 13: 3921-3929. DOI: 10.2147/OTT.S241337. doi: 10.2147/OTT.S241337
[2]	Sathirareuangchai S, Hirata K. Pulmonary lymphoepithelioma-like carcinoma[J]. Arch Pathol Lab Med, 2019, 143(8): 1027-1030. DOI: 10.5858/arpa.2018-0149-RS. doi: 10.5858/arpa.2018-0149-RS pmid: 30672338
[3]	Chang YL, Wu CT, Shih JY, et al. New aspects in clinicopathologic and oncogene studies of 23 pulmonary lymphoepithelioma-like carcinomas[J]. Am J Surg Pathol, 2002, 26(6): 715-723. DOI: 10.1097/00000478-200206000-00004. doi: 10.1097/00000478-200206000-00004
[4]	Yeh YC, Ho HL, Lin CI, et al. Whole-exome sequencing of Epstein-Barr virus-associated pulmonary carcinoma with low lymphocytic infiltration shows molecular features similar to those of classic pulmonary lymphoepithelioma-like carcinoma: evidence to support grouping together as one disease entity[J]. Am J Surg Pathol, 2021, 45(11): 1476-1486. DOI: 10.1097/PAS.0000000000001722. doi: 10.1097/PAS.0000000000001722
[5]	赵丰年, 赵云晴, 谢永生, 等. 原发性肺淋巴上皮瘤样癌的CT表现及文献复习[J]. 国际医学放射学杂志, 2018, 41(6): 658-661. DOI: 10.19300/j.2018.L6455zt. doi: 10.19300/j.2018.L6455zt
[6]	Lei Y, Zhou J, Liu J, et al. The CT and PET/CT findings in primary pulmonary lymphoepithelioma-like carcinoma with pathological correlation: a study of 215 cases[J]. Clin Radiol, 2022, 77(3): e201-e207. DOI: 10.1016/j.crad.2021.10.010. doi: 10.1016/j.crad.2021.10.010 pmid: 35012737
[7]	Su TP, Ho KC, Wang CW, et al. Prognostic value and clinical impact of pretreatment FDG PET in pulmonary lymphoepithelioma-like carcinoma[J]. Clin Nucl Med, 2019, 44(2): e68-e75. DOI: 10.1097/RLU.0000000000002371. doi: 10.1097/RLU.0000000000002371
[8]	Li Y, Zhang W, Zhang H, et al. Prognostic significance of regional/systemic metabolic parameters on ¹⁸F-FDG PET in pulmonary lymphoepithelioma-like carcinoma[J]. Front Oncol, 2021, 11: 675961. DOI: 10.3389/fonc.2021.675961. doi: 10.3389/fonc.2021.675961
[9]	Tao L, Chen Y, Huang Y, et al. SSTR2a is constantly expressed in lymphoepithelioma-like carcinoma with squamous differentiation other than that with glandular differentiation[J]. J Clin Pathol, 2021, 74(11): 704-708. DOI: 10.1136/jclinpath-2020-206903. doi: 10.1136/jclinpath-2020-206903 pmid: 33132215
[10]	Shang Q, Pang Y, Meng T, et al. ⁶⁸Ga-DOTATATE PET/CT in primary pulmonary lymphoepithelioma-like carcinoma[J]. Clin Nucl Med, 2022, 47(2): 187-189. DOI: 10.1097/RLU.0000000000003857. doi: 10.1097/RLU.0000000000003857
[11]	Becnel D, Abdelghani R, Nanbo A, et al. Pathogenic role of Epstein-Barr virus in lung cancers[J]. Viruses, 2021, 13(5): 877. DOI: 10.3390/v13050877. doi: 10.3390/v13050877
[12]	Wu YX, Zhang WL, Wang TM, et al. Genomic landscapes of Epstein-Barr virus in pulmonary lymphoepithelioma-like carcinoma[J]. J Virol, 2022, 96(4): e0169321. DOI: 10.1128/JVI.01693-21. doi: 10.1128/JVI.01693-21
[13]	Li L, Ma BBY, Chan ATC, et al. Epstein-Barr virus-induced epigenetic pathogenesis of viral-associated lymphoepithelioma-like carcinomas and natural killer/T-cell lymphomas[J]. Pathogens, 2018, 7(3): 63. DOI: 10.3390/pathogens7030063. doi: 10.3390/pathogens7030063
[14]	Hong S, Liu D, Luo S, et al. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma[J]. Nat Commun, 2019, 10(1): 3108. DOI: 10.1038/s41467-019-10902-w. doi: 10.1038/s41467-019-10902-w pmid: 31311932
[15]	Chen B, Zhang Y, Dai S, et al. Molecular characteristics of primary pulmonary lymphoepithelioma-like carcinoma based on integrated genomic analyses[J]. Signal Transduct Target Ther, 2021, 6(1): 6. DOI: 10.1038/s41392-020-00382-6. doi: 10.1038/s41392-020-00382-6
[16]	Zheng X, Wang J, Wei L, et al. Epstein-Barr virus microRNA miR-BART5-3p inhibits p53 expression[J]. J Virol, 2018, 92(23): e01022-18. DOI: 10.1128/JVI.01022-18. doi: 10.1128/JVI.01022-18
[17]	Ngan RK, Yip TT, Cheng WW, et al. Clinical role of circulating Epstein-Barr virus DNA as a tumor marker in lymphoepithelioma-like carcinoma of the lung[J]. Ann N Y Acad Sci, 2004, 1022: 263-270. DOI: 10.1196/annals.1318.041. doi: 10.1196/annals.1318.041
[18]	Xie M, Wu X, Wang F, et al. Clinical significance of plasma Epstein-Barr virus DNA in pulmonary lymphoepithelioma-like carcinoma (LELC) patients[J]. J Thorac Oncol, 2018, 13(2): 218-227. DOI: 10.1016/j.jtho.2017.10.031. doi: S1556-0864(17)33062-9 pmid: 29191777
[19]	Chen B, Chen X, Zhou P, et al. Primary pulmonary lymphoepithe-lioma-like carcinoma: a rare type of lung cancer with a favorable outcome in comparison to squamous carcinoma[J]. Respir Res, 2019, 20(1): 262. DOI: 10.1186/s12931-019-1236-2. doi: 10.1186/s12931-019-1236-2
[20]	Li QW, Qiu B, Hu WM, et al. Plasma Epstein-Barr virus-deoxyri-bonucleic acid copy number predicts disease progression in stage Ⅰ-Ⅲ pulmonary lymphoepithelioma-like carcinoma[J]. Front Oncol, 2020, 10: 1487. DOI: 10.3389/fonc.2020.01487. doi: 10.3389/fonc.2020.01487 pmid: 32974179
[21]	Yin K, Feng HB, Li LL, et al. Low frequency of mutation of epidermal growth factor receptor (EGFR) and arrangement of anaplastic lymphoma kinase (ALK) in primary pulmonary lym-phoepithelioma-like carcinoma[J]. Thorac Cancer, 2020, 11(2): 346-352. DOI: 10.1111/1759-7714.13271. doi: 10.1111/1759-7714.13271
[22]	Xie Z, Liu L, Lin X, et al. A multicenter analysis of genomic profiles and PD-L1 expression of primary lymphoepithelioma-like carcinoma of the lung[J]. Mod Pathol, 2020, 33(4): 626-638. DOI: 10.1038/s41379-019-0391-9. doi: 10.1038/s41379-019-0391-9
[23]	Chau SL, Tong JH, Chow C, et al. Distinct molecular landscape of Epstein-Barr virus associated pulmonary lymphoepithelioma-like carcinoma revealed by genomic sequencing[J]. Cancers (Basel), 2020, 12(8): 2065. DOI: 10.3390/cancers12082065. doi: 10.3390/cancers12082065
[24]	Fan Y, Shan Q, Gong J, et al. Molecular and clinical characteristics of primary pulmonary lymphoepithelioma-like carcinoma[J]. Front Mol Biosci, 2021, 8: 736940. DOI: 10.3389/fmolb.2021.736940. doi: 10.3389/fmolb.2021.736940
[25]	Qin Y, Gao G, Xie X, et al. Clinical features and prognosis of pulmonary lymphoepithelioma-like carcinoma: summary of eighty-five cases[J]. Clin Lung Cancer, 2019, 20(3): e329-e337. DOI: 10.1016/j.cllc.2018.12.014. doi: 10.1016/j.cllc.2018.12.014
[26]	Wu Z, Xian X, Wang K, et al. Immune checkpoint blockade therapy may be a feasible option for primary pulmonary lymphoe-pithelioma-like carcinoma[J]. Front Oncol, 2021, 11: 626566. DOI: 10.3389/fonc.2021.626566. doi: 10.3389/fonc.2021.626566
[27]	Xiao Y, He J, Luo S, et al. Comparison of immunotherapy, chemotherapy, and chemoimmunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma: a retrospective study[J]. Front Oncol, 2022, 12: 820302. DOI: 10.3389/fonc.2022.820302. doi: 10.3389/fonc.2022.820302
[28]	Lin Z, Fu S, Zhou Y, et al. First-line platinum-based chemotherapy and survival outcomes in locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma[J]. Lung Cancer, 2019, 137: 100-107. DOI: 10.1016/j.lungcan.2019.09.007. doi: S0169-5002(19)30640-3 pmid: 31568886
[29]	Zhang X, Zhou Y, Chen H, et al. PD-1 inhibition plus platinum-based chemotherapy (PBC) or PBC alone in the first-line treatment of locally advanced or metastatic pulmonary lymphoepithelioma-like carcinoma[J]. Front Immunol, 2022, 13: 1015444. DOI: 10.3389/fimmu.2022.1015444. doi: 10.3389/fimmu.2022.1015444
[30]	Chang YL, Yang CY, Lin MW, et al. PD-L1 is highly expressed in lung lymphoepithelioma-like carcinoma: a potential rationale for immunotherapy[J]. Lung Cancer, 2015, 88(3): 254-259. DOI: 10.1016/j.lungcan.2015.03.017. doi: 10.1016/j.lungcan.2015.03.017
[31]	Zhong YM, Yin K, Chen Y, et al. PD-1/PD-L1 combined with LAG3 is associated with clinical activity of immune checkpoint inhibitors in metastatic primary pulmonary lymphoepithelioma-like carcinoma[J]. Front Immunol, 2022, 13: 951817. DOI: 10.3389/fimmu.2022.951817. doi: 10.3389/fimmu.2022.951817
[32]	Narayanan A, Knollmann FD, Walby JAS, et al. EBV-positive primary pulmonary lymphoepithelioma-like carcinoma response to PD-L1 blockade[J]. Clin Lung Cancer, 2019, 20(3): e238-e241. DOI: 10.1016/j.cllc.2018.12.015. doi: 10.1016/j.cllc.2018.12.015
[33]	Qiu ZX, Zhou P, Wang K. Primary pulmonary lymphoepithelioma-like carcinoma response favorably to nivolumab: a case report[J]. Onco Targets Ther, 2019, 12: 8595-8600. DOI: 10.2147/OTT.S219512. doi: 10.2147/OTT.S219512
[34]	Archwamety A, Ruangchira-Urai R, Akewanlop C, et al. Primary pulmonary lymphoepithelioma-like carcinoma treated with immunotherapy: a case report and literature review[J]. Thorac Cancer, 2022, 13(17): 2539-2541. DOI: 10.1111/1759-7714.14580. doi: 10.1111/1759-7714.14580 pmid: 35830974
[35]	Kim C, Rajan A, DeBrito PA, et al. Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature[J]. Transl Lung Cancer Res, 2016, 5(6): 720-726. DOI: 10.21037/tlcr.2016.11.06. doi: 10.21037/tlcr.2016.11.06
[36]	Simoni Y, Becht E, Li S, et al. Partial absence of PD-1 expression by tumor-infiltrating EBV-specific CD8⁺T cells in EBV-driven lymphoepithelioma-like carcinoma[J]. Clin Transl Immunology, 2020, 9(9): e1175. DOI: 10.1002/cti2.1175. doi: 10.1002/cti2.1175
[37]	Tang Z, Fang R, Tong G, et al. Overcoming resistance to anti-PD-1 immunotherapy in lymphoepithelioma-like carcinoma: a case report and review of the literature[J]. Lung Cancer, 2020, 146: 335-340. DOI: 10.1016/j.lungcan.2020.06.027. doi: S0169-5002(20)30501-8 pmid: 32623076
[38]	Liu Y, Long L, Liu J, et al. Case report: anlotinib reverses nivolumab resistance in advanced primary pulmonary lymphoe-pithelioma-like carcinoma with FGFR3 gene amplification[J]. Front Oncol, 2021, 11: 749682. DOI: 10.3389/fonc.2021.749682. doi: 10.3389/fonc.2021.749682
[39]	Bao H, Ma LZ, Zhao C, et al. Anti-angiogenic therapy for advanced primary pulmonary lymphoepithelioma-like carcinoma: a retrospective multicenter study[J/OL]. J Cancer Res Clin Oncol. [2022-04-04]. https://pubmed.ncbi.nlm.nih.gov/35377040/. DOI: 10.1007/s00432-022-03935-0. doi: 10.1007/s00432-022-03935-0
[40]	Wu Q, Wang W, Zhou P, et al. Primary pulmonary lymphoepithe-lioma-like carcinoma is characterized by high PD-L1 expression, but low tumor mutation burden[J]. Pathol Res Pract, 2020, 216(8): 153043. DOI: 10.1016/j.prp.2020.153043. doi: 10.1016/j.prp.2020.153043
[41]	Jiang L, Wang L, Li PF, et al. Positive expression of programmed death ligand-1 correlates with superior outcomes and might be a therapeutic target in primary pulmonary lymphoepithelioma-like carcinoma[J]. Onco Targets Ther, 2015, 8: 1451-1457. DOI: 10.2147/OTT.S84234. doi: 10.2147/OTT.S84234
[42]	Fang W, Hong S, Chen N, et al. PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival[J]. Oncotarget, 2015, 6(32): 33019-33032. DOI: 10.18632/oncotarget.5028. doi: 10.18632/oncotarget.5028 pmid: 26361045
[43]	Tang L, Chen N, He W, et al. The clinicopathological features and prognosis of primary pulmonary lymphoepithelioma-like carcinoma: a systematic review and meta-analysis[J]. PLoS One, 2020, 15(10): e0240729. DOI: 10.1371/journal.pone.0240729. doi: 10.1371/journal.pone.0240729